Intracom Telecom and Geolinks Demonstrate Multi-Gigabit Performance in Landmark U.S. Trial
Nationwide Licensed Spectrum and FWA Tech Enable WISPs to Deliver Fiber-Like, Interference-Free Connectivity
This successful trial advances GeoLinks commercial use of its licensed spectrum within its own footprint and empowers WISPs across 1,300
Demonstrated Live at WISPAPALOOZA
The platform showcased exceptional capabilities by connecting to terminal devices across
Watch the video news release here: Fiber-Like Speeds Anywhere | Intracom Telecom & GeoLinks
"GeoLinks is redefining what's possible in fixed wireless," said GeoLinks CEO
"We are excited and honored to join forces with GeoLinks in bringing licensed spectrum access to WISPs," said
Intracom Telecom's WiBAS™
About GeoLinks
GeoLinks is a national leader in fixed wireless and hybrid broadband solutions, providing enterprise-grade connectivity, advanced networking, and public-private network construction. Through its multi-gigabit network and proprietary ClearFiber™ technology, GeoLinks is redefining how high-speed internet is deployed in rural, suburban, and urban communities. Headquartered in
About Intracom Telecom
Intracom Telecom is a global leader in telecommunication systems and solutions with over 45 years of experience. The company's state-of-the-art FWA and transmission products serve major network operators and verticals in more than 70 countries worldwide. The WiBAS G5 platform is specifically designed for licensed mmWave spectrum, delivering over 22 Gbps from a single base station site and 2.4Gbps per CPE, using Multi-User MIMO and Hybrid Massive Beamforming, with coverage extending up to 5 miles.
View original content:https://www.prnewswire.com/news-releases/intracom-telecom-and-geolinks-demonstrate-multi-gigabit-performance-in-landmark-us-trial-302633278.html
SOURCE Intracom Telecom
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Share repurchase programme: Transactions of week 27 2026
- Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formu
- Chris Figee to leave KPN and join ASM as CFO
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share